🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method

Recruitingn/aAges 2 Years - 45 YearsAllUniversity Hospital, Clermont-Ferrand
NCT07141862 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In prepubertal patients, cryopreservation of ovarian or testicular tissue is currently the only available method for fertility preservation prior to gonadotoxic cancer treatments. However, this approach carries the risk of reintroducing malignant cells upon autotransplantation, particularly in cases of metastatic cancers such as neuroblastoma and Ewing sarcoma. Therefore, it is crucial to employ highly sensitive techniques to detect minimal residual disease (MRD) in preserved gonadal tissues. This study aims to identify the most effective detection method by comparing the sensitivity and specificity of reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR) in identifying MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues from patients treated for these malignancies during infancy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Women of any age diagnosed with a benign cyst requiring laparoscopy may be included. * Men of any age diagnosed with a non-obstructive azoospermia may be included. * Prepubertal girls and boys diagnosed with neuroblastoma or Ewing sarcoma during infancy may be included. * Capable of providing written informed consent to participate in the research study * Affiliated with a social welfare service. * For prepubertal patients, written informed consent to participate in the research study must be provided by their parents or legal guardians. Exclusion Criteria: * None
💊

What it tests

  • RT-qPCR
  • ddPCR
📍

Where

1 site
University hospital
Clermont-Ferrand, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy